Higher patient cost-sharing is associated with a lower likelihood of treatment augmentation in patients with depression who are treated with antidepressants.
Zhun Cao, PhD
Advertisement
Articles by Zhun Cao, PhD
Prior authorization for pregabalin in commercial insurance plans accomplished the objective of lower pregabalin utilization; however, there was no significant decrease in disease-related healthcare costs.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
US Employer Health Care Costs Projected to Rise 9.5% in 2027
2
FDA Approves Nipocalimab-aahu as First Treatment for wAIHA
3
FDA Clears First Single-Biomarker Blood Test for Alzheimer
4
Lung Cancer Task Force Maps Research Roadmap to Close Survival Gap
5